Last checked at 
NetScientific PLC - London-based life sciences and sustainability, technology investment and commercialisation firm - Portfolio company PDS Biotechnology Corp temporarily suspends recruitment for its National Cancer Institute-led Phase 2 clinical trial evaluating PDS0101, or Versamune-HPV16, in combination with two investigational immune-modulating agents in advanced HPV cancers.
"The issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination. It is anticipated that this temporary suspension in recruitment for this clinical trial will be determined in a timely manner and is not expected to affect the overall timing of clinical data," NetScientific says.
PDS Biotech Chief Medical Officer Lauren Wood adds: "We know from the interim data that this combination has the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options. While the trial is experiencing a slight administrative delay, we are pleased to report that the PDS0101 trial recruitment has progressed well and it is anticipated that it will resume recruitment shortly."
Current stock price: 98.10 pence, closing down 20% on Thursday
Year-to-date change: doubled from 46.50p
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.